Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease.
Mikhailova E, Semchenkova A, Illarionova O, Kashpor S, Brilliantova V, Zakharova E, Zerkalenkova E, Zangrando A, Bocharova N, Shelikhova L, Diakonova Y, Zhogov V, Khismatullina R, Molostova O, Buldini B, Raykina E, Larin S, Olshanskaya Y, Miakova N, Novichkova G, Maschan M, Popov AM. Mikhailova E, et al. Among authors: molostova o. Br J Haematol. 2021 May;193(3):602-612. doi: 10.1111/bjh.17382. Epub 2021 Mar 14. Br J Haematol. 2021. PMID: 33715150
Immunophenotypic changes in leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia after treatment with CD19-directed chimeric antigen receptor (CAR)- expressing T cells.
Mikhailova E, Illarionova O, Shelikhova L, Zerkalenkova E, Molostova O, Olshanskaya Y, Novichkova G, Maschan A, Maschan M, Popov A. Mikhailova E, et al. Among authors: molostova o. Haematologica. 2022 Apr 1;107(4):970-974. doi: 10.3324/haematol.2021.279677. Haematologica. 2022. PMID: 34911282 Free PMC article. No abstract available.
Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients.
Maschan M, Caimi PF, Reese-Koc J, Sanchez GP, Sharma AA, Molostova O, Shelikhova L, Pershin D, Stepanov A, Muzalevskii Y, Suzart VG, Otegbeye F, Wald D, Xiong Y, Wu D, Knight A, Oparaocha I, Ferencz B, Roy A, Worden A, Kruger W, Kadan M, Schneider D, Orentas R, Sekaly RP, de Lima M, Dropulić B. Maschan M, et al. Among authors: molostova o. Nat Commun. 2021 Dec 10;12(1):7200. doi: 10.1038/s41467-021-27312-6. Nat Commun. 2021. PMID: 34893603 Free PMC article.
Haploidentical donor-derived memory CAR T cells: first in human experience and in vitro correlative study.
Ukrainskaya V, Molostova O, Shelikhova L, Pershin D, Kulakovskaya E, Volkov D, Rakhteenko A, Muzalevskii Y, Kazachenok A, Brilliantova V, Osipova D, Rubtsov Y, Stepanov A, Maschan M. Ukrainskaya V, et al. Among authors: molostova o. Blood Adv. 2022 Oct 11;6(19):5582-5588. doi: 10.1182/bloodadvances.2021006262. Blood Adv. 2022. PMID: 35446932 Free PMC article. No abstract available.
CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study.
Jacoby E, Ghorashian S, Vormoor B, De Moerloose B, Bodmer N, Molostova O, Yanir AD, Buechner J, Elhasid R, Bielorai B, Rogosic S, Dourthe ME, Maschan M, Rossig C, Toren A, von Stackelberg A, Locatelli F, Bader P, Zimmermann M, Bourquin JP, Baruchel A. Jacoby E, et al. Among authors: molostova o. Leukemia. 2022 Jun;36(6):1525-1532. doi: 10.1038/s41375-022-01546-9. Epub 2022 Apr 25. Leukemia. 2022. PMID: 35468946
Extended characterization of anti-CD19 CAR T cell products manufactured at the point of care using the CliniMACS Prodigy system: comparison of donor sources and process duration.
Malakhova E, Pershin D, Kulakovskaya E, Vedmedskaia V, Fadeeva M, Lodoeva O, Sozonova T, Muzalevskii Y, Kazachenok A, Belchikov V, Shelikhova L, Molostova O, Volkov D, Maschan M. Malakhova E, et al. Among authors: molostova o. Cytotherapy. 2024 Jun;26(6):567-578. doi: 10.1016/j.jcyt.2024.02.025. Epub 2024 Mar 2. Cytotherapy. 2024. PMID: 38493403